The Relationship between Plasma Microparticles, Protein S and Anticardiolipin Antibodies in Patients with Human Immunodeficiency Virus Infection

Summary

The high prevalence of free protein S deficiency in human immunodeficiency virus (HlV)-infected patients is poorly understood. We studied 38 HIV seropositive patients. Free protein S antigen values assayed using the polyethylene-glycol precipitation technique (PEG-fS) were statistically lower in patients than in controls. These values using a specific monoclonal antibody-based ELISA (MoAb-fS) and the values of protein S activity (S-act) were not statistically different between patients and controls. C4b-binding protein values were not different from control values. In patients, PEG-fS values were lower than MoAb-fS values. Ten patients had a PEG-fS deficiency, 4 patients had a MoAb-fS deficiency and 8 had a S-act deficiency. Protein S activity and MoAb-fS were lower in clinical groups with poor prognosis and in patients with AIDS but PEG-fS was not. A trend for reduced S-act/MoAb-fS ratios was observed in patients. PEG-fS was negatively correlated with anticardiolipin antibody titers whereas MoAb-fS was not. The plasma of PEG-fS deficient HIV-patients contained high amounts of flow cytometry detectable microparticles which were depleted from plasma by PEG precipitation. The microparticles were partly CD42b and CD4 positive but CD8 negative. These microparticles were labelled by an anti free protein S monoclonal antibody. The observed differences between MoAb-fS and PEG-fS values were correlated with the amount of detectable plasma microparticles, just like the differences between MoAb-fS and S-act. Plasma microparticles correlated with anticardiolipin antibody titers.

In summary, free protein S antigen in HIV infected patients is underestimated when the PEG precipitation technique is used due to the presence of elevated levels of microparticles that bind protein S. The activity of free protein S is also impaired by high levels of microparticles. The prevalence of free protein S deficiency in HIV positive patients is lower than previously published (4/38, -10%) and is correlated with poor prognosis. By implication, use of a PEG precipitation technique might give artefactually low free protein S antigen values in other patient groups if high numbers of microparticles are present. In HIV patients, high titers of anticardiolipin antibodies are associated with high concentrations of cell-derived plasma microparticles.

• References

• 1 Walker JF. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem 1981; 256: 11128-11130
• 2 Griffin JH, Gruber A, Fernandez JA. Reevaluation of total, free and bound protein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin. Blood 1992; 79: 3203-3211
• 3 Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082-2086
• 4 Schwartz HP, Fisher M, Hopmeier P, Batard MA, Griffin JH. Plasma proteinS deficiencies in familial thrombotic disease. Blood 1984; 64: 1297-1300
• 5 Comp PC, Doray D, Patton D, Esmon CT. An abnormal plasma distribution of proteinS occurs in functional proteinS deficiency. Blood 1986; 67: 504-508
• 6 Amiral J, Grosley B, Boyer-Neumann C, Marfaing-Koka A, Peynaud-Debayle E, Wolf M, Meyer D. New direct assay of free protein S antigen using two distinct monoclonal antibodies specific for the free form. Blood Coag Fibrinol 1994; 5: 179-186
• 7 Schved JF, Gris JC, Michaud A, Amiral J, Quincat D, Arnaud A, Martinez P. Study of the protein S system in HIV-infected patients: acquired protein S deficiency or unsuitable assays. Blood Coag Fibrinol 1992; 3: 295-301
• 8 Lafeuillade A, Alessi MC, Poizot-Martin I, Boyer-Neumann C, Zandotti C, Quilichini R, Aubert L, Tamalet C, Juhan-Vague I, Gastaud JA. Endothelial cell dysfunction in HIV infection. J Acquir Immune Defic Syndr 1992; 5: 127-131
• 9 Bissuel F, Berruyer M, Causse X, Dechavanne M, Trepo C. Acquired protein S deficiency: correlation with advanced disease in HIV-1 infected patients. J Acquir Immune Defic Syndr 1992; 5: 484-489
• 10 Stahl CP, Wideman CS, Spira TJ, Haff EC, Hixon GJ, Evatt BL. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993; 81: 1801-1807
• 11 Sorice M, Griggi T, Arcieri P, Circella A, d’Agostino F, Ranieri M, Modrzewska R, Lenti L, Mariani G. Protein S and HIV infection. The role of anticardiolipin and anti-protein S antibodies Thromb Res 1994; 73: 165-171
• 12 Toulon P, Lamine M, Ledjev I, Guez T, Holleman ME, Sereni D, Sicard D. Heparin II cofactor deficiency in patients infected with the human immunodeficiency virus. Thromb Haemost 1993; 70: 730-735
• 13 Hassell KL, Kressin DC, Neumann A, Ellison RE, Marlar RA. Correlation of antiphospholipid antbodies and protein S deficiency with thrombosis in HIV-infected men. Blood Coag Fibrinol 1994; 5: 455-462
• 14 Centers for Disease Control. Revision of the case definition of acquired immunodeficiency syndrome for national reporting, United States. MMWR 1985 34. 372-375
• 15 Bounameaux H, Schneider PA, Reber G, de Moerloose P, Kraheubuhl B. Measurement of plasma D-dimer for diagnosis of deep venous thrombosis. Am J Clin Pathol 1989; 91: 82-85
• 16 Amiral J, Adam M, Plassart F, Mimard Vissac AM. Immunoassays for the measurement of PS. in Gaffney PJ. eds Fibrinolysis: Current Prospects, New York: John Libbey & Co.; 1988: 125-128
• 17 Wolf M, Boyer-Neumann C, Martinolli JL, Leroy-Matheron C, Amiral J, Meyer D, Larrieu MJ. A new functional assay for human protein S activity using factor V as substrate. Thromb Haemost 1989; 4: 1144-1145
• 18 Angles-Cano E. A spectrophotometric solid-phase-fibrin-tissue plasminogen activator activity assay (SOFIA-tPA) for high-fibrin-affinity tissue plasminogen activators. Anal Biochem 1986; 153: 201-210
• 19 Dahlback B. Purification of human vitamin K-dependent protein S and its limited proteolysis by thrombin. Biochem J 1983; 209: 847-856
• 20 Eckle I, Seitz R, Egbring R, Kolb G, Havemann K. Protein S degradation in vitro by neutrophil elastase. Scand J Clin Lab Invest 1993; 53: 281-288
• 21 Marfaing-Koka A, Boyer-Neumann C, Wolf M, Leroy-Matheron C, Cyno-ber T, Tchernia G. Decreased protein S activity in sickle cell disease. Nouv Rev FrHematol 1993; 35: 425-430
• 22 Lane PA, O’Connell JL, Marlar RA. Erythrocyte membrane vesicles and irreversibly sickled cells bind protein S. Am J Hematol 1994; 47: 295-300
• 23 Ginsberg JS, Demers C, Brill-Edwards P, Bona R, Johnston M, Wong A, Denburg JA. Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus. Am J Med 1995; 98: 379-383
• 24 Dahlback B, Wiedmer T, Esmon CT, Sims PJ. Assembly of protein S and protein C on platelet microparticles. Thromb Haemost 1991; 65: 710
• 25 Holme PA, Solum NO, Brosstad F, Roger M, Abdelnoor M. Demonstration of platelet-derived microvesicles in blood from patients with activated coagulation and fibrinolysis using a filtration technique and western blotting. Thromb Haemost 1994; 72: 666-671
• 26 Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JAI, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin indiced thrombocytopenia. Blood 1994; 84: 3691-3699
• 27 Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362: 355-360
• 28 D’Angelo AD, Vigano-D’Angelo S, Esmon CT, Comp PC. Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, in liver disease and in disseminated intravascular coagulation. J Clin Invest 1988; 81: 1445-1454
• 29 Hooper CW, Philips DJ, Ribeiro MJA, Benson JM, George VG, Ades EW, Evatt BL. Tumor necrosis factor alpha downregulates protein S secretion in microvascular and umbilical vein endothelial cells but not in the HepG-2 hepatoma cell line. Blood 1994; 84: 483-489
• 30 Schved JF, Gris JC, Amaud A, Martinez P, Sanchez N, Wautier JL, Sarlat C. Von Willebrand factor antigen, tissue-type plasminogen activator antigen and risk of death in human immunodeficiency virus 1-related clinical disease: independent pronostic relevance of tissue-type plasminogen activator. J Lab Clin Med 1992; 120: 411-419
• 31 Fan ST, Shia K, Edgington TS. Upregulation of human immunodeficiency virus-1 in chronically infected monocytic cell line by both contact with endothelial cells and cytokines. Blood 1994; 84: 1567-1572